OG
OGN
Organon & Co.
$13.44
-0.07%
$3.5B
No data for this timeframe.
Vol
Market Cap$3.5B
Cap SizeMid Cap
Analyst ConsensusSell (0%)
Inst. Holders50 funds
Inst. Value$811.0M
Inst. Activity17 buys / 20 sells
Insider Activity1B / 1S
Insider Net $$0.00
SEC Reports11
Recent Activity
Jun 11, 2026
SEC
Organon filed a DEFA14A (additional definitive proxy soliciting material) containing a transcript of an internal all-emp
DEFA14A — Impact 3/10
Jun 1, 2026
SEC
Organon & Co. has filed a preliminary proxy statement (PREM14A) in connection with its proposed acquisition by Sun Pharm
PREM14A — Impact 8/10
May 27, 2026
SEC
The court consolidated two securities fraud class actions against Organon & Co. and appointed the Michigan Regional Coun
COURT-RULING — Impact 4/10
May 6, 2026
Insider
Holzbaur Lynette sold 26,448.366 shares
SVP and Corporate Controller @ $13.35 ($353.1K)
May 6, 2026
Insider
Holzbaur Lynette acquired 45.939 shares
SVP and Corporate Controller
May 6, 2026
Insider
Holzbaur Lynette bought 26,448.366 shares
SVP and Corporate Controller @ $13.35 ($353.1K)
Inst.
CANADA PENSION PLAN INVESTMENT — DOUBLED
5,011,100 shares ($30.0M)
Inst.
FIRST TRUST ADVISORS LP — ADD
3,227,320 shares ($19.3M)
Price Targets
$11.25
-16.3% upside
Strong Sell
Current $13.44
Low $8.00
Median $11.50
High $14.00
4 analysts
$8.00
$14.00
Analyst Ratings
0Strong Buy
0Buy
7Hold
5Sell
1Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 29, 2026 | BNP Paribas | DOWNGRADE | Outperform → Neutral |
| Apr 28, 2026 | Piper Sandler | UPGRADE | Underweight → Neutral |
| Feb 24, 2026 | Barclays | MAINTAIN | Underweight → Underweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.92 ▼ -1.8% | $0.82 — $1.07 | -8% YoY | 6 |
| Next Q | $0.93 ▼ -2.1% | $0.88 — $1.05 | -7% YoY | 6 |
| Current FY | $3.44 ▼ -0.7% | $3.30 — $3.72 | -6% YoY | 7 |
| Next FY | $3.66 ▼ -1.8% | $3.41 — $3.82 | 6% YoY | 7 |
Latest Reports
NEUTRAL
DEFA14A
3/10
Organon filed a DEFA14A (additional definitive proxy soliciting material) containing a transcript of an internal all-emp
Jun 11, 2026
BULLISH
PREM14A
8/10
Organon & Co. has filed a preliminary proxy statement (PREM14A) in connection with its proposed acquisition by Sun Pharm
Jun 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Erste Asset Management GmbH | — | — |
| BlackRock, Inc. | $190.0M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $130.9M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $70.3M | — |
| STATE STREET CORP | $59.6M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 6, 2026 | Holzbaur Lynette | SELL | $353.1K |
| May 6, 2026 | Holzbaur Lynette | J | $0.00 |
| May 6, 2026 | Holzbaur Lynette | BUY | $353.1K |
| Mar 31, 2026 | Drinane Juliana | M | $0.00 |
| Mar 31, 2026 | Drinane Juliana | F | $12.5K |
50 institutional holders with $811.0M total value (135,197,712 shares) as of 2026-Q1. Top holders: Erste, BlackRock,, VANGUARD. Net selling activity: 20 institutions trimmed/exited vs 17 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Erste Asset Management GmbH | — | $0.00 | 0.0% | — |
| 2 | BlackRock, Inc. | 31,717,028 | $190.0M | 23.4% | — |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 21,846,036 | $130.9M | 16.1% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 11,737,018 | $70.3M | 8.7% | — |
| 5 | STATE STREET CORP | 9,956,774 | $59.6M | 7.4% | — |
| 6 | CANADA PENSION PLAN INVESTMENT BOARD | 5,011,100 | $30.0M | 3.7% | DOUBLED +106.2% |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3,362,349 | $20.1M | 2.5% | — |
| 8 | MORGAN STANLEY | 3,292,684 | $19.7M | 2.4% | TRIM -27.0% |
| 9 | DIMENSIONAL FUND ADVISORS LP | 3,265,280 | $19.6M | 2.4% | — |
| 10 | FIRST TRUST ADVISORS LP | 3,227,320 | $19.3M | 2.4% | ADD +78.1% |
| 11 | TWO SIGMA INVESTMENTS, LP | 3,137,020 | $18.8M | 2.3% | DOUBLED +238.4% |
| 12 | D. E. Shaw & Co., Inc. | 2,644,552 | $15.8M | 2.0% | DOUBLED +590.0% |
| 13 | FMR LLC | 2,558,692 | $15.3M | 1.9% | DOUBLED +7142.9% |
| 14 | Cerity Partners LLC | 2,309,039 | $13.8M | 1.7% | DOUBLED +111.5% |
| 15 | Invesco Ltd. | 2,226,714 | $13.3M | 1.6% | ADD +38.1% |
| 16 | CITADEL ADVISORS LLC | 1,998,390 | $12.0M | 1.5% | — |
| 17 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1,689,210 | $10.1M | 1.2% | NEAR_EXIT -75.5% |
| 18 | VANGUARD FIDUCIARY TRUST CO | 1,612,057 | $9.7M | 1.2% | — |
| 19 | GOLDMAN SACHS GROUP INC | 1,605,325 | $9.6M | 1.2% | — |
| 20 | Parallax Volatility Advisers, L.P. | 1,602,000 | $9.6M | 1.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| CANADA PENSION PLAN INVESTMENT BOARD | DOUBLED | 2,429,740 | 5,011,100 | +106.2% | $30.0M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | ADD | 1,812,081 | 3,227,320 | +78.1% | $19.3M | 2026-Q1 |
| FMR LLC | DOUBLED | 35,327 | 2,558,692 | +7142.9% | $15.3M | 2026-Q1 |
| Cerity Partners LLC | DOUBLED | 1,091,714 | 2,309,039 | +111.5% | $13.8M | 2026-Q1 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | NEAR_EXIT | 6,882,166 | 1,689,210 | -75.5% | $10.1M | 2026-Q1 |
| Gotham Asset Management, LLC | TRIM | 2,653,817 | 1,257,055 | -52.6% | $7.5M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 439,967 | 933,176 | +112.1% | $5.6M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,779,848 | 738,502 | -58.5% | $4.4M | 2026-Q1 |
| FRANKLIN RESOURCES INC | TRIM | 497,882 | 282,913 | -43.2% | $1.7M | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | ADD | 131,552 | 246,852 | +87.6% | $1.5M | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 655,731 | 238,000 | -63.7% | $1.4M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 104,400 | 190,057 | +82.0% | $1.1M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 129,375 | 167,327 | +29.3% | $1.0M | 2026-Q1 |
| State of Tennessee, Department of Treasury | TRIM | 167,061 | 107,295 | -35.8% | $642.7K | 2026-Q1 |
| ROYCE & ASSOCIATES LP | ADD | 59,878 | 93,576 | +56.3% | $560.5K | 2026-Q1 |
| Jain Global LLC | TRIM | 127,332 | 84,732 | -33.5% | $507.5K | 2026-Q1 |
| Amundi | ADD | 43,983 | 80,944 | +84.0% | $484.9K | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 3,176 | 68,821 | +2066.9% | $412.2K | 2026-Q1 |
| CWM, LLC | TRIM | 82,542 | 50,836 | -38.4% | $304.5K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | TRIM | 76,547 | 44,952 | -41.3% | $285.9K | 2026-Q1 |
| NOMURA HOLDINGS INC | TRIM | 78,836 | 37,200 | -52.8% | $222.8K | 2026-Q1 |
| Vanguard Personalized Indexing Management, LLC | ADD | 28,654 | 36,396 | +27.0% | $218.0K | 2026-Q1 |
| Freestone Grove Partners LP | TRIM | 53,737 | 30,774 | -42.7% | $184.3K | 2026-Q1 |
| Atria Investments, Inc | DOUBLED | 11,491 | 28,406 | +147.2% | $170.2K | 2026-Q1 |
| COMMONWEALTH EQUITY SERVICES, LLC | TRIM | 39,607 | 26,726 | -32.5% | $160.1K | 2026-Q1 |
10 unique insiders with 50 transactions. Net insider value: $0.00 ($353.1K bought, $353.1K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 6, 2026 | Holzbaur Lynette | SVP and Corporate Controller | SELL | 26,448.366 | $13.35 | $353.1K |
| May 6, 2026 | Holzbaur Lynette | SVP and Corporate Controller | J | 45.939 | — | — |
| May 6, 2026 | Holzbaur Lynette | SVP and Corporate Controller | BUY | 26,448.366 | $13.35 | $353.1K |
| Mar 31, 2026 | Drinane Juliana Papa | Interim Head of Mfg & Supply | EXERCISE | 6,378 | — | — |
| Mar 31, 2026 | Drinane Juliana Papa | Interim Head of Mfg & Supply | TAX W/H | 2,185 | $5.70 | $12.5K |
| Mar 31, 2026 | Drinane Juliana Papa | Interim Head of Mfg & Supply | AWARD | 125,208 | — | — |
| Mar 31, 2026 | Morrissey Joseph T. Jr. | Interim CEO | TAX W/H | 2,221 | $5.70 | $12.7K |
| Mar 31, 2026 | Morrissey Joseph T. Jr. | Interim CEO | AWARD | 333,889 | — | — |
| Mar 31, 2026 | Morrissey Joseph T. Jr. | Interim CEO | EXERCISE | 7,795 | — | — |
| Mar 31, 2026 | Holzbaur Lynette | SVP and Corporate Controller | EXERCISE | 4,252 | — | — |
| Mar 31, 2026 | Weaver Kirke | Gen. Counsel & Corp. Secy. | TAX W/H | 1,767 | $5.70 | $10.1K |
| Mar 31, 2026 | Nisita Vittorio | Head of Global Business Svcs | EXERCISE | 4,606 | — | — |
| Mar 31, 2026 | Holzbaur Lynette | SVP and Corporate Controller | TAX W/H | 1,212 | $5.70 | $6.9K |
| Mar 31, 2026 | Holzbaur Lynette | SVP and Corporate Controller | AWARD | 75,125 | — | — |
| Mar 31, 2026 | Weaver Kirke | Gen. Counsel & Corp. Secy. | EXERCISE | 6,201 | — | — |
| Mar 31, 2026 | Falcione Aaron | Chief Human Resources Officer | TAX W/H | 2,306 | $5.70 | $13.1K |
| Mar 31, 2026 | Nisita Vittorio | Head of Global Business Svcs | TAX W/H | 1,578 | $5.70 | $9.0K |
| Mar 31, 2026 | Nisita Vittorio | Head of Global Business Svcs | AWARD | 125,208 | — | — |
| Mar 31, 2026 | Weaver Kirke | Gen. Counsel & Corp. Secy. | AWARD | 183,639 | — | — |
| Mar 31, 2026 | Falcione Aaron | Chief Human Resources Officer | AWARD | 166,944 | — | — |
| Mar 31, 2026 | Falcione Aaron | Chief Human Resources Officer | EXERCISE | 6,732 | — | — |
| Mar 31, 2026 | WALSH MATTHEW M | Chief Financial Officer | TAX W/H | 4,127 | $5.70 | $23.5K |
| Mar 31, 2026 | Stahler Rachel A | Chief Information Officer | AWARD | 183,639 | — | — |
| Mar 31, 2026 | Stahler Rachel A | Chief Information Officer | EXERCISE | 6,555 | — | — |
| Mar 31, 2026 | Stahler Rachel A | Chief Information Officer | TAX W/H | 2,246 | $5.70 | $12.8K |
| Mar 31, 2026 | WALSH MATTHEW M | Chief Financial Officer | EXERCISE | 12,047 | — | — |
| Mar 31, 2026 | WALSH MATTHEW M | Chief Financial Officer | AWARD | 321,368 | — | — |
| Mar 31, 2026 | Karp Daniel | Executive VP, Corp. Dev. | EXERCISE | 11,338 | — | — |
| Mar 31, 2026 | Karp Daniel | Executive VP, Corp. Dev. | TAX W/H | 3,554 | $5.70 | $20.3K |
| Mar 31, 2026 | Karp Daniel | Executive VP, Corp. Dev. | AWARD | 100,166 | — | — |
| Mar 31, 2026 | Arjona Ferreira Juan Camilo | Head of R&D & CMO | AWARD | 200,333 | — | — |
| Mar 31, 2026 | Arjona Ferreira Juan Camilo | Head of R&D & CMO | TAX W/H | 4,820 | $5.70 | $27.5K |
| Mar 31, 2026 | Arjona Ferreira Juan Camilo | Head of R&D & CMO | EXERCISE | 13,431 | — | — |
| Mar 29, 2026 | Morrissey Joseph T. Jr. | Interim CEO | EXERCISE | 9,752 | — | — |
| Mar 29, 2026 | Morrissey Joseph T. Jr. | Interim CEO | TAX W/H | 2,779 | $5.84 | $16.2K |
| Mar 29, 2026 | WALSH MATTHEW M | Chief Financial Officer | EXERCISE | 15,071 | — | — |
| Mar 29, 2026 | WALSH MATTHEW M | Chief Financial Officer | TAX W/H | 5,162 | $5.84 | $30.1K |
| Mar 29, 2026 | Falcione Aaron | Chief Human Resources Officer | EXERCISE | 8,422 | — | — |
| Mar 29, 2026 | Falcione Aaron | Chief Human Resources Officer | TAX W/H | 2,885 | $5.84 | $16.8K |
| Mar 29, 2026 | Arjona Ferreira Juan Camilo | Head of R&D & CMO | EXERCISE | 8,865 | — | — |
| Mar 29, 2026 | Arjona Ferreira Juan Camilo | Head of R&D & CMO | TAX W/H | 3,181 | $5.84 | $18.6K |
| Mar 29, 2026 | Drinane Juliana Papa | Interim Head of Mfg & Supply | EXERCISE | 7,979 | — | — |
| Mar 29, 2026 | Drinane Juliana Papa | Interim Head of Mfg & Supply | TAX W/H | 2,733 | $5.84 | $16.0K |
| Mar 29, 2026 | Nisita Vittorio | Head of Global Business Svcs | EXERCISE | 5,762 | — | — |
| Mar 29, 2026 | Nisita Vittorio | Head of Global Business Svcs | TAX W/H | 1,974 | $5.84 | $11.5K |
| Mar 29, 2026 | Weaver Kirke | Gen. Counsel & Corp. Secy. | EXERCISE | 7,757 | — | — |
| Mar 29, 2026 | Weaver Kirke | Gen. Counsel & Corp. Secy. | TAX W/H | 2,210 | $5.84 | $12.9K |
| Mar 29, 2026 | Karp Daniel | Executive VP, Corp. Dev. | EXERCISE | 14,184 | — | — |
| Mar 29, 2026 | Karp Daniel | Executive VP, Corp. Dev. | TAX W/H | 4,446 | $5.84 | $26.0K |
| Mar 29, 2026 | Holzbaur Lynette | SVP and Corporate Controller | EXERCISE | 5,319 | — | — |
11 SEC filing reports analyzed. Sentiment: 5 bullish, 1 bearish, 0 mixed, 5 neutral. Avg impact: 5.7/10.
NEUTRAL
DEFA14A
3/10
Organon filed a DEFA14A (additional definitive proxy soliciting material) containing a transcript of
Jun 11, 2026
BULLISH
PREM14A
8/10
Organon & Co. has filed a preliminary proxy statement (PREM14A) in connection with its proposed acqu
Jun 1, 2026
NEUTRAL
COURT-RULING
4/10
The court consolidated two securities fraud class actions against Organon & Co. and appointed the Mi
May 27, 2026
NEUTRAL
DEFA14A
3/10
Organon filed this DEFA14A as additional soliciting material in support of its pending acquisition b
Apr 30, 2026
BEARISH
8-K
6/10
Organon reported Q1 2026 revenue of $1.460B (-4% YoY as-reported, -9% ex-FX) and GAAP diluted EPS of
Apr 30, 2026
BULLISH
DEFA14A
7/10
Organon management filed this DEFA14A to communicate with employees following the definitive merger
Apr 27, 2026
NEUTRAL
DEFA14A
5/10
Organon filed additional definitive proxy soliciting materials (DEFA14A) containing a transcript of
Apr 27, 2026
BULLISH
DEFA14A
9/10
Organon & Co. filed additional proxy materials in support of its pending acquisition by Sun Pharmace
Apr 27, 2026
BULLISH
DEFA14A
8/10
Organon & Co. has entered into a definitive merger agreement with Sun Pharmaceutical, under which Su
Apr 27, 2026
BULLISH
8-K
8/10
Organon & Co. has entered into a definitive merger agreement with Sun Pharmaceutical, under which Su
Apr 27, 2026
NEUTRAL
DEFA14A
2/10
Organon & Co. filed a definitive proxy statement for its 2026 annual meeting, seeking shareholder ap
Apr 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Sell (0% buy). Based on 13 analysts: 0 strong buy, 0 buy, 7 hold, 5 sell, 1 strong sell.
Analyst Price Targets
$11.25 mean target
-16.3% upside
Strong Sell (3.00)
$8.00 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $13.44 |
| Target Low | $8.00 |
| Target Mean | $11.25 |
| Target Median | $11.50 |
| Target High | $14.00 |
| # Analysts | 4 |
| Recommendation | Strong Sell (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.92 | $0.82 | $1.07 | -7.9% | -1.8% | 0↑ 2↓ | $1.6B | -2.4% | 6 |
| Next Q 2026-09-30 |
$0.93 | $0.88 | $1.05 | -7.4% | -2.1% | 0↑ 2↓ | $1.6B | -2.1% | 6 |
| Current FY 2026-12-31 |
$3.44 | $3.30 | $3.72 | -5.9% | -0.7% | 0↑ 2↓ | $6.1B | -1.4% | 7 |
| Next FY 2027-12-31 |
$3.66 | $3.41 | $3.82 | 6.3% | -1.8% | 2↑ 1↓ | $6.2B | 1.6% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.921 | |
| 7d ago | $0.938 | -0.017 |
| 30d ago | $0.938 | -0.017 |
| 60d ago | $0.949 | -0.029 |
| 90d ago | $1.024 | -0.103 |
3 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 29, 2026 | BNP Paribas | DOWNGRADE | Outperform | Neutral |
| Apr 28, 2026 | Piper Sandler | UPGRADE | Underweight | Neutral |
| Feb 24, 2026 | Barclays | MAINTAIN | Underweight | Underweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 7 | 5 | 1 | 0% | |
| May 1, 2026 | 0 | 1 | 6 | 5 | 1 | 8% | |
| Apr 1, 2026 | 0 | 1 | 6 | 8 | 1 | 6% | |
| Mar 1, 2026 | 0 | 1 | 6 | 8 | 1 | 6% | |
| Feb 1, 2026 | 0 | 1 | 6 | 8 | 1 | 6% | |
| Jan 1, 2026 | 0 | 1 | 6 | 8 | 1 | 6% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 12, 2026
short_volume
Short Volume: OGN — 55.7% short (0.3M / 0.5M)
Short: 294,358 | Exempt: 508 | TRF Vol: 528,612 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: OGN — 55.2% short (0.3M / 0.6M)
Short: 341,864 | Exempt: 9,128 | TRF Vol: 619,862 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: OGN — 59.7% short (0.8M / 1.3M)
Short: 777,872 | Exempt: 2,960 | TRF Vol: 1,302,231 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: OGN — 2.7M shares, 33,278 trades
Week starting 2026-05-18. Total ATS volume: 2,697,056 shares across 33,278 trades.
May 12, 2026
short_volume
Short Volume: OGN — 55.6% short (1.1M / 2.0M)
Short: 1,109,092 | Exempt: 8 | TRF Vol: 1,996,158 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
May 11, 2026
dark_pool
Dark Pool: OGN — 4.6M shares, 47,728 trades
Week starting 2026-05-11. Total ATS volume: 4,591,384 shares across 47,728 trades.
May 8, 2026
Clinical Trial
A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)
Phase Phase 2 — TERMINATED
May 8, 2026
Clinical Trial
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
Phase Phase 2 — COMPLETED
May 7, 2026
earnings_calendar
OGN Q1 2026 Earnings Scheduled — 2026-05-07
May 4, 2026
dark_pool
Dark Pool: OGN — 9.2M shares, 64,500 trades
Week starting 2026-05-04. Total ATS volume: 9,180,528 shares across 64,500 trades.
Apr 29, 2026
short_interest
FTD: OGN — 39,608 shares ($0.5M) failed to deliver
Settlement: 20260429, Price: $13.32, FTD Value: $527,578.56, ORGANON & CO
Apr 28, 2026
short_interest
FTD: OGN — 219,881 shares ($2.9M) failed to deliver
Settlement: 20260428, Price: $13.16, FTD Value: $2,893,633.96, ORGANON & CO
Apr 27, 2026
dark_pool
Dark Pool: OGN — 44.1M shares, 157,746 trades
Week starting 2026-04-27. Total ATS volume: 44,121,403 shares across 157,746 trades.
Apr 24, 2026
short_volume
Short Volume: OGN — 55.2% short (6.2M / 11.3M)
Short: 6,211,132 | Exempt: 34,640 | TRF Vol: 11,257,412 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
dark_pool
Dark Pool: OGN — 8.3M shares, 65,106 trades
Week starting 2026-04-20. Total ATS volume: 8,290,574 shares across 65,106 trades.
Apr 17, 2026
short_volume
Short Volume: OGN — 55.5% short (1.5M / 2.7M)
Short: 1,486,023 | Exempt: 0 | TRF Vol: 2,679,328 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
short_volume
Short Volume: OGN — 56.9% short (3.3M / 5.9M)
Short: 3,343,437 | Exempt: 7,063 | TRF Vol: 5,872,040 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
Clinical Trial
An Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Etonogestrel-releasing Medicated Intrauterine Systems (Study P06060)
Phase Phase 2 — COMPLETED
Mar 6, 2026
Enforcement
Joseph Hauser, Individually and on Behalf of All Others Similarly Situated v. Organon & Co., Kevin Ali and Matthew Walsh; Barry J. Lerner, Individually and on Behalf of All Others Similarly Situated v. Organon & Co., Kevin Ali, Matthew Walsh, and Juan Camilo Arjona Ferreira
Court ruling from District Court, D. New Jersey. Docket: 2:25-cv-12983
Aug 9, 2012
FDA
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE